Sudeep Pharma
Fundamental Score
Sudeep Pharma Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SUDEEPPHRM across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (32.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (35.65%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Consistent Growth Track Record (32.48% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (50.39% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (27.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 59.31x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (-35.52% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Sudeep Pharma
About SUDEEPPHRM
Company Details
SUDEEPPHRM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Sudeep Pharma (SUDEEPPHRM)?
As of 01 Dec 2025, 04:21 pm IST, Sudeep Pharma (SUDEEPPHRM) is currently trading at ₹728.20. The stock has a market capitalization of ₹8.23K (Cr).
Is SUDEEPPHRM share price Overvalued or Undervalued?
SUDEEPPHRM is currently trading at a P/E ratio of 59.31x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Sudeep Pharma share price?
Key factors influencing SUDEEPPHRM's price include its quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sudeep Pharma a good stock for long-term investment?
Sudeep Pharma shows a 5-year Profit Growth of 50.39% and an ROE of 32.77%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.28 before investing.
How does Sudeep Pharma compare with its industry peers?
Sudeep Pharma competes with major peers in the Pharmaceuticals. Investors should compare SUDEEPPHRM's P/E of 59.31x and ROE of 32.77% against the industry averages to determine its competitive standing.
What is the P/E ratio of SUDEEPPHRM and what does it mean?
SUDEEPPHRM has a P/E ratio of 59.31x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹59 for every ₹1 of annual earnings.
How is SUDEEPPHRM performing according to Bull Run's analysis?
SUDEEPPHRM has a Bull Run fundamental score of 45.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SUDEEPPHRM belong to?
SUDEEPPHRM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sudeep Pharma.
What is Return on Equity (ROE) and why is it important for SUDEEPPHRM?
SUDEEPPHRM has an ROE of 32.77%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Sudeep Pharma generates profits from shareholders' equity.
How is SUDEEPPHRM's debt-to-equity ratio and what does it indicate?
SUDEEPPHRM has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SUDEEPPHRM's dividend yield and is it a good dividend stock?
SUDEEPPHRM offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SUDEEPPHRM grown over the past 5 years?
SUDEEPPHRM has achieved 5-year growth rates of: Sales Growth 32.48%, Profit Growth 50.39%, and EPS Growth -35.52%.
What is the promoter holding in SUDEEPPHRM and why does it matter?
Promoters hold 76.15% of SUDEEPPHRM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SUDEEPPHRM's market capitalization category?
SUDEEPPHRM has a market capitalization of ₹8230 crores, placing it in the Mid-cap category.
How volatile is SUDEEPPHRM stock?
SUDEEPPHRM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SUDEEPPHRM?
SUDEEPPHRM has a 52-week high of ₹N/A and low of ₹N/A.
What is SUDEEPPHRM's operating profit margin trend?
SUDEEPPHRM has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is SUDEEPPHRM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of N/A% and YoY Profit Growth of N/A%.
What is the institutional holding pattern in SUDEEPPHRM?
SUDEEPPHRM has FII holding of 1.54% and DII holding of 14.76%. Significant institutional holding often suggests professional confidence in the stock.